AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16443257 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin plus phenprocoumon
Number of subjects: 248
Study 14715215 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling provided by physicians in the office setting
Number of subjects: 392
Study 11434052 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH (Low Molecular Weight Heparin)
Number of subjects: 0
Study 11434052 — intervention group
Group type: EXPERIMENTAL
Intervention: GP IIb/IIIa inhibitors
Number of subjects: 0
Study 11434052 — intervention group
Group type: COMPARATOR
Intervention: Proven therapies
Number of subjects: 0
Study 8980774 — intervention group
Group type: EXPERIMENTAL
Intervention: Delavirdine mesylate (400 mg)
Number of subjects: 12
Study 8980774 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (125 to 200 mg buffered tablets)
Number of subjects: 12
Study 8980774 — intervention group
Group type: EXPERIMENTAL
Intervention: Delavirdine followed by didanosine (1 h later)
Number of subjects: 12
Study 8980774 — intervention group
Group type: COMPARATOR
Intervention: Concurrent administration of delavirdine and didanosine
Number of subjects: 12
Study 8356961 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Schwarz vaccine
Number of subjects: 3
Study 8356961 — intervention group
Group type: EXPERIMENTAL
Intervention: High-titer Edmonston-Zagreb vaccine
Number of subjects: 3
Study 8356961 — intervention group
Group type: EXPERIMENTAL
Intervention: High-titer Schwarz vaccine
Number of subjects: 3
Study 8356961 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard measles vaccine
Number of subjects: 3
Study 3318426 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone, 1,000 mg at bedtime
Number of subjects: 46
Study 3318426 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 46
Study 3318426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 29438818 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Number of subjects: 60
Study 29438818 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 60
Study 29438818 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucapnic dry air
Number of subjects: 60
Study 27309537 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC)
Number of subjects: 0
Study 27309537 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study 24814592 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored smoking cessation advice (intervention group)
Number of subjects: 254
Study 24814592 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard advice)
Number of subjects: 254
Study 22290270 — intervention group
Group type: EXPERIMENTAL
Intervention: IV iron polymaltose (500 mg single dose)
Number of subjects: 104
Study 22290270 — intervention group
Group type: COMPARATOR
Intervention: PO ferrous sulfate (210 mg elemental iron daily, continuously)
Number of subjects: 104
Study 22290270 — intervention group
Group type: EXPERIMENTAL
Intervention: IV iron polymaltose
Number of subjects: 104
Study 22290270 — intervention group
Group type: COMPARATOR
Intervention: PO ferrous sulfate
Number of subjects: 104
Study 20199680 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based decision aid
Number of subjects: 0
Study 20199680 — intervention group
Group type: EXPERIMENTAL
Intervention: Print-based decision aid
Number of subjects: 0
Study 20199680 — intervention group
Group type: EXPERIMENTAL
Intervention: Both web- and print-based decision aids
Number of subjects: 0
Study 18058417 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone calls to patients after discharge
Number of subjects: 339
Study 18058417 — intervention group
Group type: COMPARATOR
Intervention: No planned contact (control group)
Number of subjects: 339
Study 16084152 — intervention group
Group type: EXPERIMENTAL
Intervention: tenecteplase combined with tirofiban
Number of subjects: 409
Study 16084152 — intervention group
Group type: COMPARATOR
Intervention: full-dose tenecteplase alone
Number of subjects: 409
Study 12360587 — intervention group
Group type: EXPERIMENTAL
Intervention: Histochrome 100 mg administered 10 min before and 1 hour after thrombolytic therapy (group 1A)
Number of subjects: 86
Study 12360587 — intervention group
Group type: EXPERIMENTAL
Intervention: Histochrome 100 mg on disease day 1 followed by 100 mg/day for 10 days (group 1B)
Number of subjects: 86
Study 12360587 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis without prophylactic histochrome (control group)
Number of subjects: 86
Study 12360587 — intervention group
Group type: EXPERIMENTAL
Intervention: Histochrome groups (1A and 1B)
Number of subjects: 86
Study 10094287 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment in the electrochemical factory (high exposure group)
Number of subjects: 1800
Study 10094287 — intervention group
Group type: COMPARATOR
Intervention: Non-workers (low exposure group)
Number of subjects: 1800
Study 7756063 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous isosorbide dinitrate
Number of subjects: 316
Study 7756063 — intervention group
Group type: COMPARATOR
Intervention: Sustained release isosorbide mononitrate
Number of subjects: 316
Study 2354706 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency transcutaneous nerve stimulation (TNS) for 20 minutes
Number of subjects: 16
Study 2354706 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 16
Study 681029 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis condition
Number of subjects: 36
Study 681029 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonhypnosis condition
Number of subjects: 36
Study 681029 — intervention group
Group type: EXPERIMENTAL
Intervention: High susceptible Ss (scoring 8-12)
Number of subjects: 36
Study 31331199 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional education (IPE) program
Number of subjects: 291
Study 31331199 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 291
Study 28144877 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal fluency tasks designed to decrease initiation impairment
Number of subjects: 2
Study 28144877 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal fluency tasks designed to enhance initiation impairment
Number of subjects: 2
Study 28144877 — intervention group
Group type: COMPARATOR
Intervention: Verbal fluency tasks (general)
Number of subjects: 2
Study 24706022 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve blocks (PNB) with an indwelling femoral nerve catheter and a single shot sciatic block
Number of subjects: 160
Study 24706022 — intervention group
Group type: COMPARATOR
Intervention: Periarticular injection (PAI) using ropivacaine, epinephrine, ketorolac, and morphine
Number of subjects: 160
Study 24706022 — intervention group
Group type: COMPARATOR
Intervention: Periarticular injection (PAI)
Number of subjects: 160
Study 24706022 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve blocks (PNB)
Number of subjects: 160
Study 23838989 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear speech
Number of subjects: 0
Study 23838989 — intervention group
Group type: EXPERIMENTAL
Intervention: Loud condition
Number of subjects: 0
Study 23838989 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow condition
Number of subjects: 0
Study 23838989 — intervention group
Group type: COMPARATOR
Intervention: Habitual condition
Number of subjects: 0
Study 23838989 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear condition
Number of subjects: 0
Study 23838989 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral and nonperipheral vowel pairs across conditions
Number of subjects: 0
Study 21990828 — intervention group
Group type: EXPERIMENTAL
Intervention: Mynx M5 (extravascular synthetic sealant)
Number of subjects: 64
Study 21990828 — intervention group
Group type: COMPARATOR
Intervention: Angio-Seal Evolution (self-tightening suture)
Number of subjects: 64
Study 18707755 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoglycemic treatment (4.72 mmol/L)
Number of subjects: 12
Study 18707755 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hyperglycemia (11.1 mmol/L)
Number of subjects: 12
Study 18707755 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade hyperglycemia (16.7 mmol/L)
Number of subjects: 12
Study 16145306 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of oral estradiol combined with 25 microg of gestodene (oE2 + G, n = 33)
Number of subjects: 152
Study 16145306 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of oral estradiol (oE2, n = 37)
Number of subjects: 152
Study 16145306 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg of transdermal 17ss-estradiol (tE2, n = 33)
Number of subjects: 152
Study 16145306 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 49)
Number of subjects: 152
Study 11933727 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyofoam/polyurethane foam dressing (Seton)
Number of subjects: 34
Study 11933727 — intervention group
Group type: COMPARATOR
Intervention: Aquagel/hydrogel dressing (Wytw.Opatrunków)
Number of subjects: 34
Study 10517313 — intervention group
Group type: COMPARATOR
Intervention: IFN monotherapy (3 x 4.5 million units IFN‐alpha 2a per week)
Number of subjects: 24
Study 10517313 — intervention group
Group type: COMPARATOR
Intervention: IFN and N‐acetylcysteine (NAC) 1.800 mg/day) plus sodium selenite (400 microg/day) supplementation
Number of subjects: 24
Study 10517313 — intervention group
Group type: COMPARATOR
Intervention: IFN, N‐acetylcysteine (NAC) 1.800 mg/day, sodium selenite (400 microg/day) plus vitamin E (544 IU/day)
Number of subjects: 24
Study 8834093 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 ml 0.9% saline)
Number of subjects: 10
Study 8834093 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (50 mg)
Number of subjects: 10
Study 1369949 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorrect positioning of endoprosthesis elements
Number of subjects: 61
Study 6946753 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking one cigarette during period 2 or period 3
Number of subjects: 13
Study 6946753 — intervention group
Group type: COMPARATOR
Intervention: Control (pre-smoking period)
Number of subjects: 13
Study 31856374 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 47
Study 31856374 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg once daily
Number of subjects: 47
Study 31801622 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated workplace mental health literacy and well-being programme delivered by a senior social worker over a period of 3 months
Number of subjects: 0
Study 31801622 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 0
Study 29083969 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational materials mailed to patients and physicians (cross-sectional cohort)
Number of subjects: 0
Study 29083969 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational materials mailed to patients and physicians (longitudinal cohort)
Number of subjects: 0
Study 29083969 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational materials mailed to patients and physicians (enhanced cohort)
Number of subjects: 0
Study 29083969 — intervention group
Group type: COMPARATOR
Intervention: No educational materials (control cohort)
Number of subjects: 0
Study 29083969 — intervention group
Group type: EXPERIMENTAL
Intervention: All cohorts
Number of subjects: 0
Study 25354238 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus conversion
Number of subjects: 30
Study 25354238 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus maintenance
Number of subjects: 30
Study 23886761 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses at the start of rehabilitation programme
Number of subjects: 14
Study 23886761 — intervention group
Group type: COMPARATOR
Intervention: Foot orthoses at the end of intervention programme
Number of subjects: 14
Study 21310836 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention to prevent excessive gestational weight gain (n = 201)
Number of subjects: 401
Study 21310836 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n = 200)
Number of subjects: 401
Study 19834961 — intervention group
Group type: EXPERIMENTAL
Intervention: Casopitant 50 mg plus ondansetron/dexamethasone
Number of subjects: 723
Study 19834961 — intervention group
Group type: EXPERIMENTAL
Intervention: Casopitant 100 mg plus ondansetron/dexamethasone
Number of subjects: 723
Study 19834961 — intervention group
Group type: EXPERIMENTAL
Intervention: Casopitant 150 mg plus ondansetron/dexamethasone
Number of subjects: 723
Study 19834961 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose casopitant 150 mg plus ondansetron/dexamethasone
Number of subjects: 723
Study 19834961 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily ondansetron plus casopitant
Number of subjects: 723
Study 19834961 — intervention group
Group type: COMPARATOR
Intervention: Control group (ondansetron/dexamethasone only)
Number of subjects: 723
Study 16696389 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligasure hemorrhoidectomy
Number of subjects: 47
Study 16696389 — intervention group
Group type: COMPARATOR
Intervention: Closed hemorrhoidectomy
Number of subjects: 47
Study 15572269 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (100-300 mg/day)
Number of subjects: 125
Study 15572269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 12165818 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 677
Study 12165818 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative cough score
Number of subjects: 677
Study 12165818 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in cough on and off PPI
Number of subjects: 677
Study 12165818 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized acid infusion test
Number of subjects: 677
Study 9917436 — intervention group
Group type: EXPERIMENTAL
Intervention: tracking/outreach
Number of subjects: 2741
Study 9917436 — intervention group
Group type: COMPARATOR
Intervention: prompting
Number of subjects: 2741
Study 9917436 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 2741
Study 9917436 — intervention group
Group type: EXPERIMENTAL
Intervention: prompting only
Number of subjects: 2741
Study 9917436 — intervention group
Group type: EXPERIMENTAL
Intervention: combined prompting with tracking/outreach
Number of subjects: 2741
Study 7496846 — intervention group
Group type: EXPERIMENTAL
Intervention: Anabolic-androgenic steroids
Number of subjects: 157
Study 7496846 — intervention group
Group type: COMPARATOR
Intervention: Nonusers of anabolic-androgenic steroids
Number of subjects: 157
Study 7496846 — intervention group
Group type: COMPARATOR
Intervention: Mr. America winners from the presteroid era (1939-1959)
Number of subjects: 157
Study 2405743 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (5 mg)
Number of subjects: 24
Study 2405743 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine (5 mg)
Number of subjects: 24
Study 2405743 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 7363445 — intervention group
Group type: EXPERIMENTAL
Intervention: FPL57787
Number of subjects: 10
Study 7363445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31369328 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic walking exercise (AQ) for 12 weeks
Number of subjects: 72
Study 31369328 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 72
Study 28248619 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum
Number of subjects: 1000
Study 28248619 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 1000
Study 26108265 — intervention group
Group type: EXPERIMENTAL
Intervention: MA 60 mg/kg/d IM and oral placebo
Number of subjects: 90
Study 26108265 — intervention group
Group type: EXPERIMENTAL
Intervention: MA 30 mg/kg/d IM and oral cimetidine 1200 mg/d
Number of subjects: 90
Study 26108265 — intervention group
Group type: COMPARATOR
Intervention: MA 30 mg/kg/d IM and oral placebo
Number of subjects: 90
Study 23895203 — intervention group
Group type: COMPARATOR
Intervention: Best Practices (BP)
Number of subjects: 185
Study 23895203 — intervention group
Group type: EXPERIMENTAL
Intervention: Best Practices + Scheduled Reduced Smoking (BP + SRS)
Number of subjects: 185
Study 22433035 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% carbamide peroxide in a tray (TW)
Number of subjects: 24
Study 22433035 — intervention group
Group type: COMPARATOR
Intervention: 14% hydrogen peroxide in strips (WS)
Number of subjects: 24
Study 19129293 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive support with CPAP
Number of subjects: 100
Study 19129293 — intervention group
Group type: COMPARATOR
Intervention: Standard support with CPAP
Number of subjects: 100
Study 19129293 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive support
Number of subjects: 100
Study 19129293 — intervention group
Group type: COMPARATOR
Intervention: Standard support
Number of subjects: 100
Study 19129293 — intervention group
Group type: EXPERIMENTAL
Intervention: APAP
Number of subjects: 100
Study 19129293 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 100
Study 17588628 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas chromatography/tandem mass spectrometry assay (GC/MS/MS)
Number of subjects: 55
Study 17588628 — intervention group
Group type: COMPARATOR
Intervention: Radioimmunoassay (RIA)
Number of subjects: 55
Study 15364318 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 112
Study 15364318 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 112
Study 15364318 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tirofiban
Number of subjects: 112
Study 15364318 — intervention group
Group type: EXPERIMENTAL
Intervention: No glycoprotein (GP) IIb/IIIa inhibitor
Number of subjects: 112
Study 15364318 — intervention group
Group type: EXPERIMENTAL
Intervention: GP IIb/IIIa inhibitor bolus followed by maintenance infusion
Number of subjects: 112
Study 12373267 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMP treatment
Number of subjects: 133
Study 9649456 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-impact exercise program of increasing intensity
Number of subjects: 117
Study 8194619 — intervention group
Group type: EXPERIMENTAL
Intervention: Human chorionic gonadotropin (hCG) with GnRH agonist
Number of subjects: 457
Study 8194619 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 457
Study 8194619 — intervention group
Group type: COMPARATOR
Intervention: Luteal phase support (general)
Number of subjects: 457
Study 8194619 — intervention group
Group type: COMPARATOR
Intervention: hCG
Number of subjects: 457
Study 2816239 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% isoflurane
Number of subjects: 60
Study 2816239 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% isoflurane
Number of subjects: 60
Study 2816239 — intervention group
Group type: COMPARATOR
Intervention: 0.5% halothane
Number of subjects: 60
Study 2816239 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (0.5% isoflurane, 1% isoflurane, 0.5% halothane)
Number of subjects: 60
Study 4614210 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% fetal calf serum (FCS)
Number of subjects: 76
Study 4614210 — intervention group
Group type: COMPARATOR
Intervention: 10% fetal calf serum (FCS)
Number of subjects: 76
Study 4614210 — intervention group
Group type: COMPARATOR
Intervention: 5% fetal calf serum (FCS)
Number of subjects: 76
Study 4614210 — intervention group
Group type: COMPARATOR
Intervention: 15-30% fetal calf serum (FCS)
Number of subjects: 76
Study 4614210 — intervention group
Group type: COMPARATOR
Intervention: Preliminary experiment (5-30% FCS)
Number of subjects: 76
Study 4614210 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard deviation estimates
Number of subjects: 76
Study 4614210 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean AF cell growth
Number of subjects: 76
Study 30260455 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 1821
Study 30260455 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 1821
Study 30260455 — intervention group
Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 1821
Study 30260455 — intervention group
Group type: COMPARATOR
Intervention: Nicotine gum
Number of subjects: 1821
Study 29453304 — intervention group
Group type: EXPERIMENTAL
Intervention: QbTest protocol (experimental arm)
Number of subjects: 60
Study 29453304 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control arm)
Number of subjects: 60
Study 29453304 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 60
Study 27525912 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Networks (ANNs)
Number of subjects: 16
Study 27525912 — intervention group
Group type: COMPARATOR
Intervention: Ward modified location model (MLM)
Number of subjects: 16
Study 22577959 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform-switched implant (test)
Number of subjects: 17
Study 22577959 — intervention group
Group type: COMPARATOR
Intervention: Platform-matched implant (control)
Number of subjects: 17
Study 22577959 — intervention group
Group type: COMPARATOR
Intervention: Both test and control implants
Number of subjects: 17
Study 22248747 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control (IGC) to maintain glucose level between 6.1 mmol/L and 8.3 mmol/L
Number of subjects: 30
Study 22248747 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 21034878 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral interventions (two types)
Number of subjects: 68
Study 21034878 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 68
Study 18803000 — intervention group
Group type: EXPERIMENTAL
Intervention: AMT 25 mg
Number of subjects: 41
Study 18803000 — intervention group
Group type: EXPERIMENTAL
Intervention: AMT 50 mg
Number of subjects: 41
Study 18803000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 16040472 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined manipulation, exercise, and physician consultation (combination group)
Number of subjects: 204